Author

John van Duzer

Observed names: J. van Duzer, John Van Duzer

Observed institutions: Eloxx Pharmaceuticals (United States), Acetylon Pharmaceuticals (United States), ActivBiotics (United States)

OpenAlex ID: A5077782519

Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2

2005 · Ronald Esser, Carol Berry, et al. · British Journal of Pharmacology · 125

Discovery of Potent Poly(ADP-ribose) Polymerase-1 Inhibitors from the Modification of Indeno[1,2-c]isoquinolinone

2005 · Prakash G. Jagtap, Erkan Baloglu, et al. · Journal of Medicinal Chemistry · 85

Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers

2019 · Andi Leubitz, Anat Frydman‐Marom, et al. · Clinical Pharmacology in Drug Development · 74

In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus

2006 · Christopher K. Murphy, Steve Mullin, et al. · Antimicrobial Agents and Chemotherapy · 42

Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injury

2023 · Kerri D. Pryce, Randal A. Serafini, et al. · Nature Neuroscience · 23

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

2015 · Ruben Niesvizky, Paul G. Richardson, et al. · Blood · 22

Rifalazil and Other Benzoxazinorifamycins in the Treatment of Chlamydia‐Based Persistent Infections

2007 · David M. Rothstein, John van Duzer, et al. · Archiv der Pharmazie · 18

Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection

2006 · David M. Rothstein, Ronald S. Farquhar, et al. · Antimicrobial Agents and Chemotherapy · 18

Activities of Rifamycin Derivatives against Wild-Type and rpoB Mutants of Chlamydia trachomatis

2005 · Minsheng Xia, Robert J. Suchland, et al. · Antimicrobial Agents and Chemotherapy · 12

Abstract 1977: ACR-2316: A potentially first-in-class, potent, selective WEE1/PKMYT1 inhibitor rationally designed for superior single agent activity through synergistic disruption of cell cycle checkpoints

2024 · Caroline Wigerup, Helén Nilsson, et al. · Cancer Research · 4

Rifalazil and Derivative Compounds Show Potent Efficacy in a Mouse Model of H. pylori Colonization

2008 · David M Rothstein, Steve Mullin, et al. · The Journal of Antibiotics · 2

CGS 26529: The biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action

1995 · E. Kimble, T. Kowalski, et al. · Inflammation Research · 1

Abstract A082: AP3-guided biological SAR enables discovery of ACR-2316, a novel clinical-stage WEE1/PKMYT1 inhibitor designed for CDK1/2 and PLK1 pathway activation

2026 · Lei Shi, Marc Isaksson, et al. · Clinical Cancer Research

Author Correction: Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injury

2024 · Kerri D. Pryce, Randal A. Serafini, et al. · Nature Neuroscience

WS06-3 Administration of ELX-02 to healthy volunteers demonstrates dose-linearity and proportionality as well as low inter-subject variability

2019 · A. Leubitz, J. van Duzer, et al. · Journal of Cystic Fibrosis

ChemInform Abstract: Rifalazil and Other Benzoxazinorifamycins in the Treatment of Chlamydia‐Based Persistent Infections

2007 · David M. Rothstein, John van Duzer, et al. · ChemInform

Works count: 16

Citation count: 424

H-index: 9

I10-index: 9